Heightened long-term cardiovascular risks after exacerbation of chronic obstructive pulmonary disease

被引:15
|
作者
Hawkins, Nathaniel M. [1 ,7 ]
Nordon, Clementine [2 ]
Rhodes, Kirsty [2 ]
Talukdar, Manisha [3 ]
Mcmullen, Suzanne [4 ]
Ekwaru, Paul [4 ]
Pham, Tram [4 ]
Randhawa, Arsh K. [3 ]
Sin, Don D. [5 ,6 ]
机构
[1] Univ British Columbia, Ctr Cardiovasc Innovat, Div Cardiol, Vancouver, BC, Canada
[2] AstraZeneca UK Ltd, Cambridge, England
[3] AstraZeneca Canada Inc, Mississauga, ON, Canada
[4] Medlior Hlth Outcomes Res Ltd, Calgary, AB, Canada
[5] Univ British Columbia, UBC Ctr Heart Lung Innovat, Vancouver, BC, Canada
[6] Univ British Columbia, Dept Med Respirol, Vancouver, BC, Canada
[7] Univ British Columbia, St Pauls Hosp, Cardiol, 1081 Burrard St, Vancouver, BC, Canada
关键词
Heart Failure; Arrhythmias; Cardiac; Risk Factors; HEART-FAILURE; COPD; INFLAMMATION; STROKE;
D O I
10.1136/heartjnl-2023-323487
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ObjectiveTo examine the risk of adverse cardiovascular (CV) events following an exacerbation of chronic obstructive pulmonary disease (COPD).MethodsThis retrospective cohort study identified patients with COPD using administrative data from Alberta, Canada from 2014 to 2019. Exposure periods were 12 months following moderate or severe exacerbations; the reference period was time preceding a first exacerbation. The primary outcome was the composite of all-cause death or a first hospitalisation for acute coronary syndrome, heart failure (HF), arrhythmia or cerebral ischaemia. Time-dependent Cox regression models estimated covariate-adjusted risks associated with six exposure subperiods following exacerbation.ResultsAmong 1 42 787 patients (mean age 68.1 years and 51.7% men) 61 981 (43.4%) experienced at least one exacerbation and 34 068 (23.9%) died during median follow-up of 64 months. The primary outcome occurred in 43 564 (30.5%) patients with an incidence rate prior to exacerbation of 5.43 (95% CI 5.36 to 5.50) per 100 person-years. This increased to 95.61 per 100 person-years in the 1-7 days postexacerbation (adjusted HR 15.86, 95% CI 15.17 to 16.58) and remained increased for up to 1 year. The risk of both the composite and individual CV events was increased following either a moderate or a severe exacerbation, though greater and more prolonged following severe exacerbation. The highest magnitude of increased risk was observed for HF decompensation (1-7 days, HR 72.34, 95% CI 64.43 to 81.22).ConclusionModerate and severe COPD exacerbations are independent risk factors for adverse CV events, especially HF decompensation. The impact of optimising COPD management on CV outcomes should be evaluated.
引用
收藏
页码:702 / 709
页数:8
相关论文
共 50 条
  • [1] Long-term inhaled corticosteroid treatment in patients with chronic obstructive pulmonary disease, cardiovascular disease, and a recent hospitalised exacerbation: The ICSLIFE pragmatic, randomised controlled study
    Papi, Alberto
    Forini, Giacomo
    Maniscalco, Mauro
    Bargagli, Elena
    Crimi, Claudia
    Santus, Pierachille
    Molino, Antonio
    Bandiera, Valeria
    Baraldi, Federico
    D'Anna, Silvestro Ennio
    Carone, Mauro
    Marvisi, Maurizio
    Pelaia, Corrado
    Scioscia, Giulia
    Patella, Vincenzo
    Aliani, Maria
    Fabbri, Leonardo M.
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2024, 128 : 104 - 111
  • [2] Cognitive dysfunction among patients in chronic obstructive pulmonary disease: Effects of exacerbation and long-term oxygen therapy
    Cilingir, Buket Mermit
    Gunbatar, Hulya
    Cilingir, Vedat
    CLINICAL RESPIRATORY JOURNAL, 2020, 14 (12) : 1137 - 1143
  • [3] Early and Long-term Outcomes of Older Adults after Acute Care Encounters for Chronic Obstructive Pulmonary Disease Exacerbation
    Genao, Liza
    Durheim, Michael T.
    Mi, Xiaojuan
    Todd, Jamie L.
    Whitson, Heather E.
    Curtis, Lesley H.
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2015, 12 (12) : 1805 - 1812
  • [4] The Impact of Anemia on Long-Term Mortality in Hospitalized Patients with Exacerbation of Chronic Obstructive Pulmonary Disease
    Garcia-Pachon, Eduardo
    Padilla-Navas, Isabel
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2024, 19 : 2229 - 2237
  • [5] Exacerbation of Chronic Obstructive Pulmonary Disease
    Xianghui Zhou
    Qingling Li
    Xincan Zhou
    Cell Biochemistry and Biophysics, 2015, 73 : 349 - 355
  • [6] Exacerbation of Chronic Obstructive Pulmonary Disease
    Zhou, Xianghui
    Li, Qingling
    Zhou, Xincan
    CELL BIOCHEMISTRY AND BIOPHYSICS, 2015, 73 (02) : 349 - 355
  • [7] Asymmetric Dimethylarginine Predicts Long-Term Outcome in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease
    Vogeli, Alaadin
    Ottiger, Manuel
    Meier, Marc A.
    Steuer, Christian
    Bernasconi, Luca
    Huber, Andreas
    Christ-Crain, Mirjam
    Henzen, Christoph
    Hoess, Claus
    Thomann, Robert
    Zimmerli, Werner
    Mueller, Beat
    Schuetz, Philipp
    LUNG, 2017, 195 (06) : 717 - 727
  • [8] Chronic bronchial infection and incident cardiovascular events in chronic obstructive pulmonary disease patients: A long-term observational study
    Martinez-Garcia, Miguel Angel
    Faner, Rosa
    Oscullo, Grace
    la Rosa-Carrillo, David
    Soler-Cataluna, Juan Jose
    Ballester, Marta
    Muriel, Alfonso
    Agusti, Alvar
    RESPIROLOGY, 2021, 26 (08) : 776 - 785
  • [9] Pathogens Isolated and Their Association With the Long-Term Outcome in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease
    Rao, C. Mohan
    Sarbhai, Kinshuk
    Subhankar, Saswat
    Mohapatra, Amrut
    Singh, Nipa
    Panda, Prem S.
    Patro, Shubhransu
    Pati, Sanghamitra
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (06)
  • [10] Cardiovascular Disease Does Not Predict Exacerbation Rate or Mortality in Chronic Obstructive Pulmonary Disease
    Jones, Paul W.
    Mullerova, Hana
    Agusti, Alvar
    Decramer, Marc
    Adamek, Lukasz
    Raillard, Alice
    Zhu, Chang-Qing
    Wedzicha, Jadwiga A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197 (03) : 400 - 403